Characterisation of the Australian adult population living with asthma: Exacerbation frequency, long-term OCS use and adverse effects.

Study identification

• EU PAS number:
  EUPAS41161
• Study ID:
  44945
• Official title and acronym:
  Characterisation of the Australian adult population living with asthma: Exacerbation frequency, long-term OCS use and adverse effects.
• DARWIN EU® study:
  No
• Study countries:
  Australia
• Study description:
  The study employs a novel multi-modal approach to analyse, describe, and categorise the Australian adult asthmatic population based on factors such as their age, exacerbation frequency and OCS reliance. An audit of asthma classification and management in the primary care setting will also be conducted simultaneously. Understanding the demographics of Australian adults diagnosed with asthma and assessing existing management practices in primary care stands to offer insights into the burden of the disease in this country and how it could be reduced. The results of this study stand to be beneficial for both the patient’s and the health care sector as identifying gaps in the management of asthma in the primary care setting can improve patient's asthma control thereby easing the burden on the Australian health care sector by limiting the number of avoidable asthma-related hospitalisations per year.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Optimum Patient Care Australia

Australia

Networks

Optimum Patient Care (OPC) Network

United Kingdom (Northern Ireland)

Respiratory Effectiveness Group (REG)

Belgium

Denmark

France

Germany

Greece

Hungary

Italy

Netherlands

Spain

Sweden

United Kingdom

Study timelines

Date when funding contract was signed

Actual: 01/05/2019

Study start date

Actual: 01/05/2019

Date of final study report

Planned: 31/12/2022

Sources of funding

Other

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca, Novartis, Optimum Patient Care Australia

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable